Altamira Therapeutics Ltd. Impairment Loss Recognised In Profit Or Loss
Altamira Therapeutics Ltd. (CYTOF) reported Impairment Loss Recognised In Profit Or Loss of -CHF 161.25 thousand for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-04-22.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ImpairmentLossRecognisedInProfitOrLoss · last filed 2025-04-30
CHF
| Period end | Impairment Loss Recognised In Profit Or Loss 12 month |
|---|---|
| 2023-12-31 | -161.25K CHF 20-F/A · filed 2024-04-22 |
USD
| Period end | Impairment Loss Recognised In Profit Or Loss 12 month |
|---|---|
| 2023-12-31 | -$179.47K 20-F · filed 2025-04-30 |